Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 36 Neoplasms 7 Neoplasm Metastasis 7 Endometrial Neoplasms 7 Ovarian Neoplasms 5 Triple Negative Breast Neoplasms 4 Breast Diseases 3 Brain Neoplasms 3 Sarcoma 2 Neoplasms by Site 2 Meningioma 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Breast Neoplasms, Male 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor, Adult 1 Sarcoma, Kaposi 1 Retinoblastoma 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Osteosarcoma 1 Neurofibromatosis 1 1 Neoplasm, Residual 1 Multiple Myeloma 1 Medulloblastoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1

Interventions

pembrolizumab 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sotorasib 1 peposertib 1 pazopanib 1 patritumab deruxtecan 1 palbociclib 1 osimertinib 1 lenvatinib 1 atezolizumab 1 amivantamab 1 abemaciclib 1 Trastuzumab 1 Tiragolumab 1 Fulvestrant 1 Cryosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Solid Tumor, Adult × abemaciclib × Clear all

NCT04092673 2024-05-21

Zotatifin

Effector Therapeutics

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡